Cannabis Ointment Shows Promise in Early Trial for Skin Disease

Topline phase 1 results from a study of a medical grade cannabis (MGC) ointment show that the topical treatment was safe and tolerable. No severe adverse events occurred in either of 2 stages of the study, and only one participant experienced minor irritation.

"We are encouraged by the positive results from this phase 1 safety trials,” said Mordechai Bignitz, Chief Executive Officer of OWC Pharmaceutical Research Corp., in a statement. “This was the first trial to assess the safety and tolerability of medical grade cannabis ointment as a topical treatment for skin diseases.”

The single-center, prospective, and placebo-controlled study consisted of 2 stages. In the first, 26 healthy participants received a single dose application of medical grade cannabis ointment (3% cannabidiol [CBD], 3% tetrahydrocannabinol [THC]). They were hospitalized and monitored for 24 hours.

The second stage assessed the safety and tolerability of multiple doses of MGC applied over 6 weeks. This stage included 20 healthy participants—13 that had previously participated in stage 1 and 7 that had not. Each participant applied the cannabis ointment (daily dose 30 mg CBD, 30 mg THC) to one arm and a placebo ointment (vehicle only) to the other arm. Participants applied the treatments twice per day, at home. Investigators were blinded as to which treatment was applied to which arm.

The study was conducted at Sheba Academic Medical Center in Israel from September 2017 to January 2019.

OWC Pharmaceutical Research Corp. reported that a phase 2 study of medical grade cannabis ointment for the treatment of psoriasis will begin in the third quarter of 2019.
 

This article was originally published by MD Magazine.




Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Data from an analysis of multiple phase 3 studies highlight improvements in mobility, self-care, and usual activities for patients with moderate-to-severe psoriasis taking secukinumab (Cosentyx).
The study through Penn State College of Medicine adds to existing research on the benefits of medical cannabis in cancer cases.
Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the need for increased pharmacy benefit manager regulation on a federal level.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$